TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04197921: Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

Sponsor: InSightec · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 29 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$896,400

Rescue Site Savings

+$597,600

Unlock Full NCT04197921 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04197921 Rescue Dossier →